CELLECTAR NEW22 DL-00001
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more
Market Cap & Net Worth: CELLECTAR NEW22 DL-00001 (NV4)
CELLECTAR NEW22 DL-00001 (F:NV4) has a market capitalization of $396.53K (€386.30K) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #37952 globally and #5012 in its home market, demonstrating a -19.39% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CELLECTAR NEW22 DL-00001's stock price €0.25 by its total outstanding shares 1536000 (1.54 Million).
CELLECTAR NEW22 DL-00001 Market Cap History: 2015 to 2025
CELLECTAR NEW22 DL-00001's market capitalization history from 2015 to 2025. Data shows change from $181.32 Million to $396.53K (-46.83% CAGR).
CELLECTAR NEW22 DL-00001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CELLECTAR NEW22 DL-00001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NV4 by Market Capitalization
Companies near CELLECTAR NEW22 DL-00001 in the global market cap rankings as of March 19, 2026.
Key companies related to CELLECTAR NEW22 DL-00001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
CELLECTAR NEW22 DL-00001 Historical Marketcap From 2015 to 2025
Between 2015 and today, CELLECTAR NEW22 DL-00001's market cap moved from $181.32 Million to $ 396.53K, with a yearly change of -46.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €396.53K | -0.98% |
| 2024 | €400.47K | -88.56% |
| 2023 | €3.50 Million | +48.00% |
| 2022 | €2.36 Million | -74.58% |
| 2021 | €9.30 Million | -65.50% |
| 2020 | €26.96 Million | -10.47% |
| 2019 | €30.11 Million | +51.59% |
| 2018 | €19.87 Million | -88.96% |
| 2017 | €179.90 Million | -5.47% |
| 2016 | €190.30 Million | +4.96% |
| 2015 | €181.32 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of CELLECTAR NEW22 DL-00001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $396.53K USD |
| MoneyControl | $396.53K USD |
| MarketWatch | $396.53K USD |
| marketcap.company | $396.53K USD |
| Reuters | $396.53K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.